Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Decitabine limits escape from MEK inhibition in uveal melanoma.

Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM.

Pigment Cell Melanoma Res. 2019 Nov 23. doi: 10.1111/pcmr.12849. [Epub ahead of print]

PMID:
31758842
2.

Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.

Piña Y, Fusco MJ, Macaulay RJ, Walko CM, Peguero E, Evernden BR, Smalley KS, Forsyth P.

J Neurol. 2019 Nov 21. doi: 10.1007/s00415-019-09575-8. [Epub ahead of print]

PMID:
31748891
3.

Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Chen YA, Teer JK, Eroglu Z, Wu JY, Koomen JM, Karreth FA, Messina JL, Smalley KSM.

Semin Cancer Biol. 2019 Nov 2. pii: S1044-579X(19)30343-8. doi: 10.1016/j.semcancer.2019.10.017. [Epub ahead of print] Review.

PMID:
31689494
4.

Transcriptomic and Single-Cell Analysis of the Murine Parotid Gland.

Oyelakin A, Song EAC, Min S, Bard JE, Kann JV, Horeth E, Smalley K, Kramer JM, Sinha S, Romano RA.

J Dent Res. 2019 Dec;98(13):1539-1547. doi: 10.1177/0022034519882355. Epub 2019 Oct 17.

PMID:
31623513
5.

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.

Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Eroglu Z, Sondak VK, Messina JL, Babacan NA, Maria-Engler SS, De Armas L, Williams SL, Gatenby RA, Chen YA, Anderson ARA, Smalley KSM.

EBioMedicine. 2019 Oct;48:178-190. doi: 10.1016/j.ebiom.2019.09.023. Epub 2019 Oct 5.

6.

MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.

Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA.

Cancer Res. 2019 Nov 15;79(22):5812-5825. doi: 10.1158/0008-5472.CAN-19-0698. Epub 2019 Jul 30.

PMID:
31362929
7.

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM.

Clin Cancer Res. 2019 Sep 15;25(18):5686-5701. doi: 10.1158/1078-0432.CCR-18-3382. Epub 2019 Jun 21.

PMID:
31227503
8.

Which behaviour change techniques are most effective in improving healthcare utilisation in COPD self-management programmes? A protocol for a systematic review.

Smalley KR, Aufegger L, Flott K, Holt G, Mayer EK, Darzi A.

BMJ Open Respir Res. 2019 Apr 11;6(1):e000369. doi: 10.1136/bmjresp-2018-000369. eCollection 2019.

9.

Pharmacological research and cancer: A call to arms.

Smalley KSM.

Pharmacol Res. 2019 Aug;146:104291. doi: 10.1016/j.phrs.2019.104291. Epub 2019 May 31. No abstract available.

PMID:
31158465
10.

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling.

Yin Q, Han T, Fang B, Zhang G, Zhang C, Roberts ER, Izumi V, Zheng M, Jiang S, Yin X, Kim M, Cai J, Haura EB, Koomen JM, Smalley KSM, Wan L.

Nat Commun. 2019 Apr 23;10(1):1870. doi: 10.1038/s41467-019-09844-0.

11.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM.

Cancer Res. 2019 Jun 1;79(11):2947-2961. doi: 10.1158/0008-5472.CAN-19-0040. Epub 2019 Apr 15.

PMID:
30987999
12.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
13.

Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology.

Mancera N, Smalley KSM, Margo CE.

Surv Ophthalmol. 2019 May - Jun;64(3):272-288. doi: 10.1016/j.survophthal.2018.12.002. Epub 2018 Dec 20. Review.

PMID:
30578807
14.

ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).

Alves-Fernandes DK, Oliveira ÉA, Faião-Flores F, Alicea-Rebecca G, Weeraratna AT, Smalley KSM, Barros SBM, Maria-Engler SS.

Pharmacol Res. 2019 Mar;141:63-72. doi: 10.1016/j.phrs.2018.12.006. Epub 2018 Dec 11.

PMID:
30550954
15.

Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats.

Fong LY, Jing R, Smalley KJ, Wang ZX, Taccioli C, Fan S, Chen H, Alder H, Huebner K, Farber JL, Fiehn O, Croce CM.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11091-E11100. doi: 10.1073/pnas.1813956115. Epub 2018 Nov 5.

16.

Frontiers in pigment cell and melanoma research.

Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF.

Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. doi: 10.1111/pcmr.12728. Epub 2018 Oct 3.

17.

Genetic and scRNA-seq Analysis Reveals Distinct Cell Populations that Contribute to Salivary Gland Development and Maintenance.

Song EC, Min S, Oyelakin A, Smalley K, Bard JE, Liao L, Xu J, Romano RA.

Sci Rep. 2018 Sep 19;8(1):14043. doi: 10.1038/s41598-018-32343-z.

18.

The Impact of Rurality on Likelihood of Drunk Driving and Riding With a Driver Under the Influence Among High School Students.

Smalley KB, Warren JC, Tarasenko YN, Barefoot KN.

J Rural Health. 2019 Jun;35(3):354-361. doi: 10.1111/jrh.12321. Epub 2018 Aug 30.

PMID:
30160320
19.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.

Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM.

Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19.

20.

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 May 15;124(10):2254-2255. doi: 10.1002/cncr.31261. Epub 2018 Mar 15. No abstract available.

21.

Functional characterization and genomic studies of a novel murine submandibular gland epithelial cell line.

Min S, Song EC, Oyelakin A, Gluck C, Smalley K, Romano RA.

PLoS One. 2018 Feb 20;13(2):e0192775. doi: 10.1371/journal.pone.0192775. eCollection 2018.

22.

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?

Smalley I, Smalley KSM.

Cancer Discov. 2018 Feb;8(2):140-142. doi: 10.1158/2159-8290.CD-17-1355.

23.

Why do women with melanoma do better than men?

Smalley KS.

Elife. 2018 Jan 16;7. pii: e33511. doi: 10.7554/eLife.33511.

24.

The biology and therapeutic management of melanoma brain metastases.

Abate-Daga D, Ramello MC, Smalley I, Forsyth PA, Smalley KSM.

Biochem Pharmacol. 2018 Jul;153:35-45. doi: 10.1016/j.bcp.2017.12.019. Epub 2017 Dec 24. Review.

25.

Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.

Faião-Flores F, Smalley KSM.

J Invest Dermatol. 2018 Jan;138(1):10-13. doi: 10.1016/j.jid.2017.07.001.

26.

The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.

Smalley KSM, Forsyth PA.

Pharmacol Res. 2018 Sep;135:265-267. doi: 10.1016/j.phrs.2017.11.013. Epub 2017 Nov 13. No abstract available.

PMID:
29146209
27.

Integration of metabolomics, transcriptomics, and microRNA expression profiling reveals a miR-143-HK2-glucose network underlying zinc-deficiency-associated esophageal neoplasia.

Fong LY, Jing R, Smalley KJ, Taccioli C, Fahrmann J, Barupal DK, Alder H, Farber JL, Fiehn O, Croce CM.

Oncotarget. 2017 Jun 9;8(47):81910-81925. doi: 10.18632/oncotarget.18434. eCollection 2017 Oct 10.

28.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM.

Mol Cancer Ther. 2018 Jan;17(1):73-83. doi: 10.1158/1535-7163.MCT-17-0196. Epub 2017 Nov 13.

29.

Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.

Phadke M, Remsing Rix LL, Smalley I, Bryant AT, Luo Y, Lawrence HR, Schaible BJ, Chen YA, Rix U, Smalley KSM.

Mol Oncol. 2018 Jan;12(1):74-88. doi: 10.1002/1878-0261.12152. Epub 2017 Nov 23.

30.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.

31.

Discrepancy in Motivation for Weight Loss and Exercise in Rural Patients.

Warren JC, Smalley KB, Barefoot KN.

Am J Health Behav. 2017 Nov 1;41(6):803-809. doi: 10.5993/AJHB.41.6.14.

32.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 Jan 15;124(2):297-305. doi: 10.1002/cncr.30946. Epub 2017 Oct 12.

33.

Recent Alcohol, Tobacco, and Substance Use Variations between Rural and Urban Middle and High School Students.

Warren JC, Smalley KB, Barefoot KN.

J Child Adolesc Subst Abuse. 2017;26(1):60-65. doi: 10.1080/1067828X.2016.1210550. Epub 2016 Aug 24.

34.

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Naci H, Smalley KR, Kesselheim AS.

JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415.

35.

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.

Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.

36.

BRAF-MEK inhibition in melanoma brain metastases: a new hope.

Forsyth PA, Smalley KSM, Sondak VK.

Lancet Oncol. 2017 Jul;18(7):836-837. doi: 10.1016/S1470-2045(17)30449-7. No abstract available.

PMID:
28677560
37.

SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer.

Li J, Smalley I, Schell MJ, Smalley KSM, Chen YA.

Bioinformatics. 2017 Sep 15;33(18):2951-2953. doi: 10.1093/bioinformatics/btx297.

38.

Making melanoma therapy personal: an interview with Dr Keiran Smalley for Melanoma Management.

Smalley KS.

Melanoma Manag. 2017 May;4(2):95-97. doi: 10.2217/mmt-2017-0001. Epub 2017 May 19.

39.

Women's health care: the experiences and behaviors of rural and urban lesbians in the USA.

Barefoot KN, Warren JC, Smalley KB.

Rural Remote Health. 2017 Jan-Mar;17(1):3875. Epub 2017 Mar 1.

40.

Discrepancy between Actual and Perceived Weight Status in Rural Patients: Variations by Race and Gender.

Smalley KB, Warren JC, Morrissey BD.

J Health Care Poor Underserved. 2017;28(1):514-527. doi: 10.1353/hpu.2017.0037.

41.

Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells.

Massaro RR, Faião-Flores F, Rebecca VW, Sandri S, Alves-Fernandes DK, Pennacchi PC, Smalley KSM, Maria-Engler SS.

Pharmacol Res. 2017 May;119:242-250. doi: 10.1016/j.phrs.2017.02.013. Epub 2017 Feb 14.

42.

Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies.

Sahebjam S, Forsyth PA, Smalley KS, Tran ND.

Cancer Control. 2017 Jan;24(1):42-46. Review.

PMID:
28178711
43.

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

Sharma R, Fedorenko I, Spence PT, Sondak VK, Smalley KS, Koomen JM.

J Proteome Res. 2016 Dec 2;15(12):4476-4489. Epub 2016 Nov 17.

44.

Ethnic Identity Attachment and Motivation for Weight Loss and Exercise Among Rural, Overweight, African-American Women.

Smalley KB, Warren JC, McClendon S, Peacock W, Caro M.

Clin Med Insights Womens Health. 2016 Nov 17;9(Suppl 1):95-101. eCollection 2016.

45.

RNA-seq based transcriptomic map reveals new insights into mouse salivary gland development and maturation.

Gluck C, Min S, Oyelakin A, Smalley K, Sinha S, Romano RA.

BMC Genomics. 2016 Nov 16;17(1):923.

46.
47.

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.

Faião-Flores F, Alves-Fernandes DK, Pennacchi PC, Sandri S, Vicente AL, Scapulatempo-Neto C, Vazquez VL, Reis RM, Chauhan J, Goding CR, Smalley KS, Maria-Engler SS.

Oncogene. 2017 Mar 30;36(13):1849-1861. doi: 10.1038/onc.2016.348. Epub 2016 Oct 17.

48.

Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.

Kim E, Rebecca VW, Smalley KS, Anderson AR.

Eur J Cancer. 2016 Nov;67:213-222. doi: 10.1016/j.ejca.2016.07.024. Epub 2016 Sep 28.

49.

Increased immunity and BRAF inhibition: Yet another argument for combination therapy?

Smalley KSM.

Pharmacol Res. 2016 Nov;113(Pt A):719-720. doi: 10.1016/j.phrs.2016.06.015. Epub 2016 Jul 5. No abstract available.

PMID:
27392741
50.

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

Emmons MF, Faião-Flores F, Smalley KSM.

Biochem Pharmacol. 2016 Dec 15;122:1-9. doi: 10.1016/j.bcp.2016.06.014. Epub 2016 Jun 25. Review.

Supplemental Content

Loading ...
Support Center